unresectable BRAF V600 mutated melanoma
Showing 1 - 25 of 5,614
BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)
Completed
- BRAF V600E Unresectable or Metastatic Melanoma
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jun 9, 2022
Associated Factors, and Clinical Outcomes of Prescribing
Completed
- BRAF v600 Mutated Metastatic Melanoma
-
East Hanover, New JerseyNovartis Pharmaceuticals
Mar 28, 2023
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the CNS
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +3 more
- Dabrafenib
- MEK-1/MEKK-1 Inhibitor E6201
-
Scottsdale, Arizona
- +2 more
Jan 4, 2023
Melanoma Trial in Tampa (XL888, Vemurafenib)
Active, not recruiting
- Melanoma
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Aug 18, 2022
Non-small-cell Lung Cancer Trial (HL-085+Vemurafenib)
Not yet recruiting
- Non-small-cell Lung Cancer
- (no location specified)
Jun 8, 2023
Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients
Recruiting
- Melanoma (Skin)
- +2 more
-
Evora, PortugalHospital Evora
May 30, 2022
Melanoma, BRAF V600 Mutation, Unresectable Melanoma Trial in Rennes (Binimetinib Oral Tablet)
Completed
- Melanoma
- +3 more
- Binimetinib Oral Tablet
-
Rennes, FranceBiotrial
Mar 31, 2023
Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive
Not yet recruiting
- Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
- Non-investigational
- (no location specified)
May 11, 2023
Malignant Melanoma, Brain Metastases Trial in Tucson (E6201, E6201 plus dabrafenib)
Terminated
- Malignant Melanoma
- Brain Metastases
- E6201
- E6201 plus dabrafenib
-
Tucson, ArizonaUniversity of Arizona Cancer Center
Mar 5, 2022
Colorectal Cancer Trial in Shanghai (VIC, Bevacizumab Plus Chemotherapy)
Recruiting
- Colorectal Cancer
- VIC
- Bevacizumab Plus Chemotherapy
-
Shanghai, ChinaDepartment of General Surgery, Zhongshan Hospital, Fudan Univers
Sep 14, 2022
BRAF V600-mutated Lung Carcinoma Treated With Combination of
Completed
- Non Small Cell Lung Cancer
- BRAF V600 Mutation
-
Créteil, France
- +1 more
Jun 29, 2022
Metastatic Malignant Tumor in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 Trial in Houston (drug,
Active, not recruiting
- Metastatic Malignant Neoplasm in the Brain
- +7 more
- Binimetinib
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Jun 15, 2022
V600-mutated BRAF Unresectable Melanoma, V600-mutated BRAF Metastatic Melanoma, Stage III or Stage IV Metastatic Melanoma That
Terminated
- V600-mutated BRAF Unresectable Melanoma
- +2 more
-
Los Angeles, California
- +5 more
May 12, 2020
BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,
Recruiting
- BRAF NP_004324.2:p.V600E
- +2 more
- Dabrafenib
- +2 more
-
Duarte, California
- +1 more
Jan 19, 2023
Metastatic Melanoma, BRAF Gene Mutation Trial in Lexington (Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg)
Recruiting
- Metastatic Melanoma
- BRAF Gene Mutation
- Nilotinib 100mg
- +5 more
-
Lexington, KentuckyMarkey Cancer Center
Jul 22, 2022
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,
Active, not recruiting
- BRAF V600E Mutation Present
- +9 more
- Dabrafenib
- +4 more
-
Boston, Massachusetts
- +1 more
Jun 28, 2022
NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)
Not yet recruiting
- Non-small Cell Lung Cancer
- +32 more
- (no location specified)
Mar 30, 2023
Tumor Skin, Metastatic Melanoma, Melanoma Trial in Orlando, Louisville (OBX-115)
Active, not recruiting
- Tumor Skin
- +2 more
- OBX-115
-
Orlando, Florida
- +1 more
Sep 28, 2023
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV Trial in Chicago
Recruiting
- Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
- +2 more
- Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
-
Chicago, IllinoisNorthwestern University
Nov 16, 2022
BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma Trial in Czechia, Italy, Spain (Encorafenib + Binimetinib)
Not yet recruiting
- BRAF V600 Mutation
- +3 more
- Encorafenib + Binimetinib
-
Olomouc, Czechia
- +5 more
Sep 14, 2021
Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 Trial (drug, biological, procedure,
Not yet recruiting
- Colon Adenocarcinoma
- +4 more
- Encorafenib
- +5 more
- (no location specified)
Jan 24, 2023